PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations
Soft sensors are first to comprehensively monitor pregnant women without wires
10 May 2021Early screening tool leads to earlier diagnosis and treatment for autism spectrum disorder
10 May 2021PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations
More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy, researchers from the Abramson Cancer Center (ACC) at the University of Pennsylvania reported online today in the Journal of Clinical Oncology. The results from the phase II trial at the ACC support the use rucaparib for pancreatic cancer patients with BRCA1, BRCA2, and PALB2 variants to help control tumor growth without the aggressive side effects of chemotherapy.
